GC Pharma

Sanfilippo,GC Pharma,Regulatory,Treatment,Regulatory

Breakthrough in Genetic Disorder Treatment: GC Pharma’s Sanfilippo Syndrome Drug Receives FDA Phase 1 Approval

SOUTH KOREA 5월 22, 2024 • 0 Comment
Sanfilippo Syndrome, also known as Mucopolysaccharidosis Type III, is a rare genetic disorder caused by the body’s inability to produce…